Market Outlook Snapshot Market Dynamics Regional Forecast Country Insights Segment Analysis Competitive Landscape Industry News report.faq_name
On This Report

Veterinary Oncology Diagnostics Market Size & Growth Forecast 2026–2035, By Segments (End-use, Animal Type, Cancer Type, Test Type), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape

Report ID: FBI 11022| Published Date: Mar-2026| Format: PDF, Excel
MARKET OUTLOOK

Market Size and Growoth Outlook

Veterinary Oncology Diagnostics Market size was more than USD 2.29 Billion in 2025 and is set to grow at a 8.4% CAGR between 2026 and 2035, exceeding USD 5.13 Billion by 2035. The industry revenue for 2026 is assessed at USD 2.46 billion.

Base Year Value (2025)
USD 2.29 Billion
CAGR (2026-2035)
8.4%
Forecast Year Value (2035)
USD 5.13 Billion
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035

Get more details on this report

Request Free Sample Report
SNAPSHOT

Veterinary Oncology Diagnostics Market Intelligence Snapshot

Regional Market Dynamics

  • North America leads with 56.60% share, driven by advanced veterinary oncology practices, higher diagnostic adoption, and strong pet healthcare spending across specialty clinics and hospitals.
  • Asia Pacific is growing at 9.49% CAGR, supported by expanding veterinary infrastructure, increasing awareness of cancer diagnostics, and rising demand for early-stage pet disease detection services.

Segment Momentum

  • Veterinary Hospitals & Clinics held a 59.9% share in 2025 because they serve as the primary point of care, integrating cancer evaluation, sample collection, diagnosis, and treatment planning into routine workflows.
  • Feline is the fastest-growing animal type as veterinary care increasingly emphasizes comprehensive oncology diagnostics for cats, improving cancer detection and supporting more informed treatment decisions.

Market Expansion Drivers

  • Rising prevalence of cancer in companion animals increasing demand for early diagnostic solutions.
  • Growing investments in veterinary cancer research accelerating development of advanced diagnostic technologies.
  • Increasing pet healthcare awareness expanding adoption of precision oncology testing in veterinary clinics.

Leading Market Participants

FORECAST SNAPSHOT

Global Market Forecast Snapshot

Market Outlook

Key companies in the veterinary oncology diagnostics market include IDEXX Laboratories, Inc. (United States), Zoetis Inc. (United States), Mars, Incorporated (Antech Diagnostics) (United States), Neogen Corporation (United States), Thermo Fisher Scientific Inc. (United States), Eurofins Scientific SE (Luxembourg), VolitionRx Limited (United States), Embark Veterinary, Inc. (United States), PetDx, Inc. (United States), Oncotect, Inc. (United States).

Regional and Segment Outlook

North America
MARKET DYNAMICS

Market Growth Drivers and Industry Trends

Rising prevalence of cancer in companion animals increasing demand for early diagnostic solutions

As cancer diagnoses become more common in dogs and cats, veterinarians are seeing more cases where treatment decisions depend on identifying tumors earlier and with greater diagnostic confidence. This is increasing demand for the veterinary oncology diagnostics market by increasing the use of screening, biopsy evaluation, molecular assays, and imaging-linked diagnostic workflows at the point when symptoms are still ambiguous. Pet owners are also more willing to authorize testing when cancer is recognized as a frequent and serious health risk in aging companion animals, which reinforces market demand for tools that can shorten time to diagnosis and help clinicians determine whether referral, surgery, or targeted treatment is appropriate.

Growing investments in veterinary cancer research accelerating development of advanced diagnostic technologies

Rising funding directed toward veterinary oncology research is strengthening market development by moving newer diagnostic platforms from experimental use into clinical application. In the veterinary oncology diagnostics market, this translates into better availability of biomarker-based tests, improved pathology techniques, and more refined genomic and liquid biopsy approaches that give clinicians more actionable information than conventional methods alone. Research-backed validation also influences purchasing and adoption decisions, since veterinary hospitals, specialty centers, and diagnostic laboratories are more likely to invest in technologies that show clearer clinical utility and fit emerging oncology care protocols.

Increasing pet healthcare awareness expanding adoption of precision oncology testing in veterinary clinics

Higher awareness of advanced pet healthcare is changing how owners and veterinarians approach cancer management, with more emphasis on tailored treatment planning rather than symptom-based intervention alone. This is increasing market penetration in the veterinary oncology diagnostics market as clinics incorporate precision oncology testing to classify tumors more accurately, assess prognosis, and guide therapy selection. The shift is especially meaningful in referral networks and progressive companion animal practices, where informed owners are seeking specialist-level care and clinicians are using diagnostic differentiation as part of a broader strategy to improve case management and justify higher-value oncology services.

Growth Driver Impact on CAGR Regulatory Influence Geographic Relevance Adoption Rate Impact Timeline
Rising prevalence of cancer in companion animals increasing demand for early diagnostic solutions 2.00% Moderate North America, Europe High Near Term
Growing investments in veterinary cancer research accelerating development of advanced diagnostic technologies 1.80% Moderate North America, Asia Pacific High Mid Term
Increasing pet healthcare awareness expanding adoption of precision oncology testing in veterinary clinics 1.50% Low Europe, Latin America Emerging Mid Term
CUSTOM RESEARCH

Unlock insights tailored to your business with our bespoke market research solutions.

Click to get your customized report now.

Request Customization →
REGIONAL FORECAST

Regional Demand Dynamics

Polymer Modified Bitumen Market
Largest Region
North America
56.60% Market Share in 2025
North America (Largest Region) vs Asia Pacific (Fastest-Growing Region)

North America held the leading regional position in 2025, accounting for a 56.60% share of the veterinary oncology diagnostics market. This leadership is underpinned by the region’s well-established companion animal care ecosystem, broader use of advanced diagnostic testing in veterinary practice, and stronger spending capacity among pet owners and specialty care providers. In practical terms, veterinary clinics and referral hospitals across the region are more likely to integrate imaging, pathology, and cancer screening workflows into routine oncology care, which keeps testing volumes elevated and supports consistent market demand.

Asia Pacific is projected to expand at a 9.49% CAGR over the forecast period in the veterinary oncology diagnostics market, driven by the gradual modernization of veterinary services and rising uptake of specialized animal healthcare. Growth is accelerating as more urban pet owners seek earlier diagnosis and more complete treatment planning for cancer cases, prompting clinics to adopt more sophisticated diagnostic capabilities. The region’s momentum is also bolstered by the expansion of veterinary infrastructure and increasing availability of oncology-focused services, which is translating into wider real-world use of diagnostic tools across both established and emerging markets.

Parameter North America Asia Pacific Europe Latin America MEA
Innovation Hub i Scale Nascent Developing Advanced
Cost-Sensitive Region i Scale Low Medium High
Regulatory Environment i Scale Restrictive Neutral Supportive
Demand Drivers i Scale Weak Moderate Strong
Development Stage i Scale Emerging Developing Developed
Adoption Rate i Scale Low Medium High
New Entrants / Startups i Scale Sparse Moderate Dense
Macro Indicators i Scale Weak Stable Strong
COUNTRY INSIGHTS

Key Country Insights

Germany 🇩🇪

Integrated Laboratory Services

Germany emphasizes integrated laboratory diagnostics that combine pathology, imaging, and biomarker testing for veterinary oncology. German veterinary networks are enhancing diagnostic consistency to improve cancer case management across referral practices.

France 🇫🇷

Clinical Oncology Collaboration

France encourages closer collaboration between veterinary specialists and diagnostic laboratories to strengthen oncology services. French practices increasingly adopt comprehensive diagnostic workflows that improve cancer classification and treatment planning for companion animals.

Italy 🇮🇹

Pathology Service Enhancement

Italy is enhancing veterinary oncology diagnostics through broader adoption of specialized pathology and laboratory services. Italian veterinary clinics are focusing on reliable diagnostic support that enables timely therapeutic decisions and improved patient management.

Japan 🇯🇵

Companion Animal Screening

Japan is increasing the use of sophisticated oncology diagnostics as companion animal healthcare becomes more preventive. Japanese veterinary clinics are incorporating advanced testing methods that support earlier identification of complex cancer conditions.

South Korea 🇰🇷

Diagnostic Technology Adoption

South Korea is expanding access to veterinary oncology diagnostics through investment in laboratory capabilities and advanced testing platforms. South Korean veterinary providers are placing greater emphasis on accurate cancer diagnosis to support individualized treatment strategies.

United States 🇺🇸

Precision Cancer Testing

The U.S. market prioritizes advanced oncology diagnostics that enable earlier cancer detection and personalized treatment planning for companion animals. Veterinary laboratories continue expanding molecular and pathology services to support more informed clinical decisions.

SEGMENT ANALYSIS

Segment Leadership and Growth Trends

Veterinary Oncology Diagnostics Market Share (%), End-use, 2025

Veterinary Hospitals & Clinics
Reference Laboratories

Go beyond the chart, access full insights & data tables

Request Free Sample Report
End-use Segment Analysis: Veterinary Hospitals & Clinics (Largest Segment) vs Reference Laboratories (Fastest-Growing Segment)

Veterinary Hospitals & Clinics held the dominant position in the veterinary oncology diagnostics market in 2025, accounting for a 59.9% share. Their leadership is underpinned by their role as the primary point of care, where cancer suspicion, initial evaluation, sample collection, and treatment planning are closely integrated into routine clinical workflows. This direct access to patients allows veterinary hospitals and clinics to capture a substantial portion of diagnostic demand, particularly when timely decision-making is critical in oncology cases.

Reference Laboratories represent the fastest-growing segment in the veterinary oncology diagnostics market as providers increasingly rely on specialized testing capabilities that may not be available in-house. Their momentum is backed by growing demand for more advanced and standardized diagnostic assessment, especially for cases that require higher testing complexity or consistent analytical quality across providers. Compared with in-clinic testing environments, reference laboratories are seeing wider adoption because they can better support expanding oncology diagnostic needs through dedicated infrastructure and broader test processing capacity.

Animal Type Segment Analysis: Canine (Largest Segment) vs Feline (Fastest-Growing Segment)

In 2025, Canine accounted for the largest position in the veterinary oncology diagnostics market with a 67.8% share. This leadership reflects the higher volume of diagnostic activity associated with dogs in veterinary practice, where cancer screening, follow-up evaluations, and disease management are more routinely pursued. The canine segment maintains its dominance because diagnostic pathways for oncology are more established in dogs, supporting consistent utilization of testing across general practice and specialized care settings.

Feline is the fastest-growing animal type segment in the veterinary oncology diagnostics market, driven by rising diagnostic attention to cats as veterinary care becomes more tailored and comprehensive. Growth is being backed by increasing willingness to investigate oncology conditions in feline patients rather than limiting care to symptomatic management alone. Relative to canine, the feline segment is expanding from a smaller base, but its momentum is strengthened by broader adoption of diagnostic workups that improve cancer detection and guide treatment decisions in cats.

Segment Sub-Segment Largest Segment Fastest Growing
End-use Reference Laboratories, Veterinary Hospitals & Clinics Veterinary Hospitals & Clinics Reference Laboratories
Animal Type Canine, Feline, Others Canine Feline
Cancer Type Lymphoma, Sarcomas, Mammary Gland Tumors, Skin Cancers, Others Skin Cancers Skin Cancers
Test Type Blood Tests, Biopsy, Genome Testing, Endoscopy, Urinalysis, Imaging Biopsy Genome Testing
Competitive Landscape

Competitive Landscape and Market Positioning

Key companies in the veterinary oncology diagnostics market:

1. IDEXX Laboratories Inc. (United States)

2. Zoetis Inc. (United States)

3. Mars Incorporated (Antech Diagnostics) (United States)

4. Neogen Corporation (United States)

5. Thermo Fisher Scientific Inc. (United States)

6. Eurofins Scientific SE (Luxembourg)

7. VolitionRx Limited (United States)

8. Embark Veterinary Inc. (United States)

9. PetDx Inc. (United States)

10. Oncotect Inc. (United States)

The veterinary oncology diagnostics market is witnessing rising innovation as demand increases for early cancer detection and precision veterinary care solutions. Diagnostic developers are expanding biomarker research, molecular testing capabilities, and AI-assisted imaging technologies to improve clinical outcomes for companion animals. Partnerships with veterinary research centers are also supporting the introduction of more advanced and accessible oncology diagnostic services.

Company Market Share Company Revenue Revenue CAGR (%) Product Portfolio Geographic Presence Innovation / R&D Focus Strategic Developments
No companies available.
🔒 This section is available as a standalone purchase. Buy only the data you need. Inquire Before Buying
Industry News

Industry Development/News

Company Name Date Key Development
Antech Apr-24 Antech launched the Nu.Q Canine Cancer Test in Europe, providing a rapid in-clinic diagnostic tool for detecting common cancers such as lymphoma and hemangiosarcoma. By delivering results in 5–10 minutes, the test enables veterinary professionals to expedite clinical decision-making and enhance the management of oncology cases in high-risk canine patients.
VolitionRx Mar-24 VolitionRx partnered with Fujifilm Vet Systems to launch the Nu.Q Vet Cancer Test in Japan. This collaboration integrates the test into Fujifilm’s extensive reference laboratory network, significantly broadening access to early cancer screening services for dogs and improving the standard of patient care for veterinary clinics across the Japanese market.
Cancan Diagnostics Sep-24 Cancan Diagnostics entered a strategic distribution partnership with Vet Planet Ltd. to commercialize the K9-LiquiDX diagnostic tool. The rollout targets markets across Mainland Europe, APAC, the Middle East, and South America, focusing on advanced early relapse detection and longitudinal monitoring of canine cancer to provide veterinarians with actionable diagnostic capabilities for improved treatment tracking.
Torigen Pharmaceuticals Dec-24 Torigen Pharmaceuticals launched the Torigen Specialty Pathology service, offering expert-reviewed cancer diagnostics with a 3-to-5 day turnaround time. The service provides actionable reporting and is designed to integrate directly with the company’s existing personalized cancer immunotherapy platforms, streamlining the diagnostic-to-treatment workflow for veterinary practitioners managing complex pet oncology cases.
Report Customization

Explore This Report

Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.

1 report.custom report.segments 2 Custom TOC 3 Related Reports

Veterinary Oncology Diagnostics Market — Custom Segments

Segment Sub-Segment
No segment data available.

Veterinary Oncology Diagnostics Market — report.custom

Custom Chapter Custom Details
No custom TOC data available.

Need a different cut of the data?

Request Custom Research
report.faq_name

How much revenue does the veterinary oncology diagnostics market generate?

In 2026 the market for veterinary oncology diagnostics is worth approximately USD 2.46 billion.

What is the forecasted size of the veterinary oncology diagnostics industry?

Veterinary Oncology Diagnostics Market size is forecast to climb from USD 2.29 billion in 2025 to USD 5.13 billion by 2035 expanding at a CAGR of over 8.4% during 2026-2035.

How is rising cancer prevalence in companion animals influencing demand for oncology diagnostics?

Cancer prevalence in companion animals is increasing demand for earlier diagnostic testing, including imaging, biopsy evaluation, and molecular assays, enabling veterinarians to identify disease sooner and improve treatment decision-making, referral timing, and clinical confidence.

How are research investments shaping adoption of advanced veterinary oncology diagnostic tools?

Growing veterinary oncology research investment is accelerating adoption of advanced diagnostics such as biomarker testing, liquid biopsies, and improved pathology tools, helping clinicians apply more precise cancer classification and treatment planning in practice.

Why are Veterinary Hospitals & Clinics the largest end-use segment in the veterinary oncology diagnostics market?

Veterinary Hospitals & Clinics held a 59.9% share in 2025 because they serve as the primary point of care, integrating cancer evaluation, sample collection, diagnosis, and treatment planning into routine workflows.

Which animal type is growing fastest in the veterinary oncology diagnostics market?

Feline is the fastest-growing animal type as veterinary care increasingly emphasizes comprehensive oncology diagnostics for cats, improving cancer detection and supporting more informed treatment decisions.

Why does North America lead the veterinary oncology diagnostics market?

North America leads with 56.60% share, driven by advanced veterinary oncology practices, higher diagnostic adoption, and strong pet healthcare spending across specialty clinics and hospitals.

What is driving Asia Pacific growth in veterinary oncology diagnostics?

Asia Pacific is growing at 9.49% CAGR, supported by expanding veterinary infrastructure, increasing awareness of cancer diagnostics, and rising demand for early-stage pet disease detection services.

What are the prominent companies operating in the veterinary oncology diagnostics landscape?

Key companies in the veterinary oncology diagnostics market include IDEXX Laboratories, Inc. (United States), Zoetis Inc. (United States), Mars, Incorporated (Antech Diagnostics) (United States), Neogen Corporation (United States), Thermo Fisher Scientific Inc. (United States), Eurofins Scientific SE (Luxembourg), VolitionRx Limited (United States), Embark Veterinary, Inc. (United States), PetDx, Inc. (United States), Oncotect, Inc. (United States).
Testimonials

Our Clients

"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."

Quality Assurance Manager

"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."

R&D Manager

"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."

Senior Marketing Manager
THE RESEARCH BEHIND THIS REPORT

Our Research Team & Methodology

Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.

THIS REPORT'S RESEARCH VERTICAL

Research Team Overview

♢
This report was prepared by the Healthcare & Medical Devices Research Team at Fundamental Business Insights, a dedicated research group specializing in the global healthcare and medical technology industry. Our analysts continuously monitor advancements in medical technologies, clinical adoption trends, regulatory developments, reimbursement policies, healthcare infrastructure investments, competitive strategies, and evolving patient care requirements to deliver timely and reliable market intelligence. The research is developed using a structured methodology that combines primary discussions with healthcare stakeholders, company financial disclosures, regulatory publications, clinical literature, government healthcare databases, medical associations, and other authoritative secondary sources. Market estimates are validated through multiple research techniques, including top-down and bottom-up analysis, before undergoing an internal quality review to ensure accuracy, consistency, and methodological integrity prior to publication.

Prepared by the Healthcare & Medical Devices Research Team

10+
Industry Verticals
100+
Countries Analyzed
5–7
Days Standard
Delivery
12k+
Research Reports
Published
On-
Demand
Customized Research
Available
6
Months Analyst
Support
PDF + XLS
Report Deliverables

Trust & Compliance

☷D&B D-U-N-S
♢GDPR & CCPA Compliant
♙ISO 9001 Certified (ISO 9001:2015)
♙SSL Encryption
▭Secure Payments
✓Confidential Handling

Research Domains

10 coverage areas
Medical Devices & Equipment Diagnostic Imaging Clinical Diagnostics Digital Health & Telemedicine Patient Monitoring Systems Surgical & Minimally Invasive Technologies Healthcare IT & Data Systems Biotechnology & Life Sciences Pharmaceutical Technologies Healthcare Delivery & Services

Research Intelligence

Executive Leadership
Product & Technology Experts
Manufacturing & Operations Leaders
Procurement & Supply Chain Professionals
Sales & Commercial Executives
Channel Partners & Distribution Networks
Enterprise Buyers & End Users
Industry Consultants & Regulatory Experts

Research Workflow & Quality Assurance

📥
01

Data Collection

Verified information gathered through primary and secondary research.

🔍
02

Data Triangulation

Cross-validation using multiple independent data sources.

📈
03

Forecast Modelling

Market estimates developed using historical trends and analytical models.

👨‍💼
04

Analyst Validation

Findings reviewed by domain experts for accuracy and consistency.

📝
05

Editorial & Quality Review

Final editorial, quality, and compliance checks before publication.

✅
06

Final Publication

Released after successful completion of the internal review process.

Report Coverage

📊 Market Assessment

  • Market Size & Forecast
  • Market Segmentation
  • Regional Analysis
  • Growth Drivers & Challenges
  • Market Dynamics

🏢 Competitive Intelligence

  • Competitive Landscape
  • Company Profiles
  • Competitive Benchmarking
  • Mergers & Acquisitions
  • Market Share Analysis or Key Company Strategies

🔍 Strategic Analysis

  • Value Chain Analysis
  • Porter's Five Forces
  • PESTLE Analysis
  • Pricing Trends
  • Supply-Demand Analysis

🚀 Future Outlook

  • Technology Landscape
  • Regulatory Landscape
  • Investment & Funding Landscape
  • Emerging Opportunities
  • Future Market Outlook

Have a question about this report or need a custom scope?

Request Customization
License

Select License Type

Single User
US$ 4,250
Buy Now
Corporate User
US$ 6,150
Buy Now

Want this data scoped to your exact question?

Tell us the segments, regions, or competitors you need answered — an analyst will confirm scope before any custom work starts.

Talk to an Analyst →